In a significant corporate move, UnitedHealth Group has agreed to sell its remaining South American operations, Banmédica, to Patria Investments, a Brazilian private equity firm, in a deal valued at around $1 billion. The final agreement was reportedly signed over the weekend, with an official announcement expected on Monday.
This transaction represents UnitedHealth’s full exit from the Latin American market, following previous divestments in Brazil and Peru. Banmédica, which operates primarily in Chile and Colombia, serves approximately 1.7 million health-plan members and manages seven hospitals and 47 medical centers as of June. The sale is part of UnitedHealth’s broader strategy to streamline operations and refocus on its core business segments, a push led by returning CEO Stephen Hemsley.
Financially, the deal is crucial for UnitedHealth as it seeks to alleviate the burden of substantial losses from its South American operations, which amounted to an $8.3 billion loss last year. This included a staggering $7.1 billion loss linked to its Brazilian operations and $1.2 billion specifically related to Banmédica. By divesting this segment, UnitedHealth aims to enhance its profitability outlook, which it recently raised in October, targeting a return to growth by 2026 and accelerating into 2027.
Looking ahead, the transaction is expected to close after requisite regulatory approvals and due diligence are completed. The timeline for these steps has not been specified, but typically such approvals can take several months depending on antitrust considerations and the regulatory landscape in both Brazil and Chile.
The market impact of this sale is expected to be significant. For shareholders, this move could enhance the company’s focus on profitable operations and potentially strengthen its financial position as it works to recover from recent losses. Employees within the Banmédica units may face uncertainties regarding their future employment under new ownership, and the broader market may react to the strategic shift as UnitedHealth continues to refine its operational focus. Overall, this deal underscores UnitedHealth's commitment to optimizing its portfolio and pursuing sustained growth in its primary markets.